Maria-Paz Viveros

Prof. Maria-Paz Viveros


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Neuropsychopharmacology
Verified
Journal Article
Closed access
ARAlejandro Aparisi Rey
Alejandro Aparisi Rey
MPMartin Purrio
Martin Purrio
MVMaria-Paz Viveros
Maria-Paz Viveros
BLBeat Lutz
Beat Lutz

1 June 2010 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
FBFrancisco J Bermudez-Silva
Francisco J Bermudez-Silva
MVMaria-Paz Viveros
Maria-Paz Viveros
JMJ.M. McPartland
J.M. McPartland
FFF. Rodriguez de Fonseca
F. Rodriguez de Fonseca

1 May 2015 in Schizophrenia Research
Verified
Journal Article
Closed access
FGFelipe Gomes
Felipe Gomes
RLRicardo Llorente
Ricardo Llorente
EDElaine Del-Bel
Elaine Del-Bel
MVMaria-Paz Viveros
Maria-Paz Viveros
MGMeritxell López Gallardo
Meritxell López Gallardo
FGFRANCISCO SILVEIRA GUIMARAES
FRANCISCO SILVEIRA GUIMARAES

29 December 2008 in Hippocampus
Verified
Journal Article
Closed access
PDF file
Juan SuárezJuan Suárez
Juan Suárez
RLRicardo Llorente
Ricardo Llorente
SRSilvana Yanina Romero-Zerbo
Silvana Yanina Romero-Zerbo
BMBeatriz Mateos
Beatriz Mateos
FBFrancisco J Bermudez-Silva
Francisco J Bermudez-Silva
MVMaria-Paz Viveros
Maria-Paz Viveros

4 September 2003 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MBMiguel Biscaia
Miguel Biscaia
SMSusana Marín
Susana Marín
BFBeatriz Fernández
Beatriz Fernández
EMEva M. Marco
Eva M. Marco
MRMarina Rubio
Marina Rubio
MVMaria-Paz Viveros
Maria-Paz Viveros

13 June 2011 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MVMaria-Paz Viveros
Maria-Paz Viveros
RLR Llorente
R Llorente
JSJ Suarez
J Suarez
ALA Llorente-Berzal
A Llorente-Berzal
MGMeritxell López Gallardo
Meritxell López Gallardo
FFF Rodriguez de Fonseca
F Rodriguez de Fonseca
This review focuses on the endocannabinoid system as a crucial player during critical periods of brain development, and how its disturbance either by early life stressful events or cannabis consumption may lead to important neuropsychiatric signs and symptoms. First we discuss the advantages and limitations of animal models within the framework of neuropsychiatric research and the crucial role of genetic and environmental factors for the establishment of vulnerable phenotypes. We are becoming aware of important sex differences that have emerged in relation to the psychobiology of cannabinoids. We will discuss sexual dimorphisms observed within the endogenous cannabinoid system, as well as those observed with exogenously administered cannabinoids. We start with how the expression of cannabinoid CB1receptors is regulated throughout development. Then, we discuss recent results showing how an experimental model of early maternal deprivation, which induces long-term neuropsychiatric symptoms, interacts in a sex-dependent manner with the brain endocannabinoid system during development. This is followed by a discussion of differential vulnerability to the pathological sequelae stemming from cannabinoid exposure during adolescence. Next we talk about sex differences in the interactions between cannabinoids and other drugs of abuse. Finally, we discuss the potential implications that organizational and activational actions of gonadal steroids may have in establishing and maintaining sex dependence in the neurobiological actions of cannabinoids and their interaction with stress.